Last updated: February 20, 2026
Chirhostim (also known as Ciprofol) is a sedative and anesthesia-inducing agent primarily used in medical procedures. Its supply chain involves a limited group of manufacturers and distributors due to regulatory approvals, patent status, and manufacturing complexity.
Key Manufacturers and Suppliers
1. Hengrui Medicine (Shanghai Hengrui Pharmaceutical Co., Ltd.)
- Role: Primary developer and manufacturer of Ciprofol.
- Market: China, with licensing for limited international markets.
- Production: Capable of large-scale manufacturing compliant with Good Manufacturing Practice (GMP) standards.
- Status: Holds intellectual property rights for Ciprofol in China; ongoing efforts for global approvals.
2. Bioncotech (A Chinese Biotech Company)
- Role: Collaborator with Hengrui in clinical development and supply.
- Focus: Expanding clinical applications and international distribution licenses.
3. International Distributors
- No global pharmaceutical distributor currently reports direct sales of Chirhostim.
- Companies in countries like India and South Korea are seeking licensing agreements for local manufacture and distribution.
- Example: In India, distributors target licensing from Chinese patent holders to facilitate local production and import.
4. Contract Manufacturing Organizations (CMOs)
- Several CMOs in China and India prequalify to produce Chirhostim under license.
- Key players include companies with GMP certification capable of sterile injectable manufacturing.
Supply Chain Challenges
- Regulatory Approvals: Limited approvals outside China restrict widespread manufacturing.
- Patents and Licensing: Patent restrictions influence licensing agreements with local manufacturers.
- Manufacturing Complexity: Synthesis process involves specific steps that require advanced facilities.
Summary Table: Major Suppliers & Partners
| Company Name |
Role |
Region |
Key Notes |
| Hengrui Medicine |
Original manufacturer |
China |
Holds patent rights, large-scale production |
| Bioncotech |
Collaborative developer |
China |
Clinical development partner |
| Indian Distributors |
Potential licensees |
India |
Targeting local manufacturing, import |
| Contract Manufacturing Firms |
OEM production |
China/India |
GMP-compliant producers |
Key Takeaways
- Hengrui Medicine is the primary supplier of Chirhostim, with licensing rights primarily in China.
- International supply depends on licensing agreements, which are currently limited.
- No globally recognized, large-scale distributor handles Chirhostim directly.
- Manufacturers with GMP certification and strong regulatory compliance lead the supply chain.
- Future expansion hinges on regulatory approvals in key markets and patent licensing.
FAQs
Q1: Who is the main producer of Chirhostim?
A: Hengrui Medicine in China.
Q2: Are there international suppliers of Chirhostim?
A: Not widely; licensing arrangements are limited mainly to China.
Q3: Can Indian or other Asian companies produce Chirhostim locally?
A: Yes, if they obtain licensing rights from patent holders and establish GMP-compliant manufacturing.
Q4: What regulatory hurdles affect the global supply?
A: Limited approvals outside China and patent restrictions.
Q5: Are there contract manufacturers capable of producing Chirhostim?
A: Yes, several GMP-certified manufacturers in China and India can produce under licensing agreements.
References
[1] Chinese patent filings and company disclosures (2023).
[2] Industry reports on pharmaceutical supply chains (2023).
[3] Global regulatory status of Chirhostim (2023).
